FDA approves Regeneron's Otarmeni (AAV gene therapy for hearing loss)

Regeneron's Otarmeni gained accelerated approval on April 23 for OTOF-related hearing loss. Additional April approvals include Idvynso (HIV-1, 4/21) and Langlara, a Lantus biosimilar (4/29).